Biotech Opportunity GP, LLC

CIK 1816370 · last filed 2023-09-21

Biotech Opportunity GP, LLC is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider bought $40.2M of NUVB.WS on Sep 21, 2023. Across all open-market trades the lifetime net is +$110.5M, making them a net buyer over the disclosed history. The firm reports its address in Napa, CA. 10 SEC filings were submitted jointly with EcoR1 Capital Fund Qualified, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$110.47M

Filer Profile

Reported Address

1370 TRANCAS STREET, SUITE 176
NAPA, CA 94558

Phone

(415) 754-3517

State of Incorporation

Related Filers

EcoR1 Capital Fund Qualified, L.P. — 10 joint filings, latest 2023-09-22

EcoR1 Capital, LLC — 10 joint filings, latest 2023-09-22

EcoR1 Venture Opportunity Fund, LP — 10 joint filings, latest 2023-09-22

OLEG NODELMAN — 10 joint filings, latest 2023-09-22

EcoR1 Panacea Holdings, LLC — 4 joint filings, latest 2021-04-13

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Nuvation Bio Inc. (NUVB.WS) Delisted	Director	3,165,000	$0.01	$16.1K	$72.32M	2	2023-09-21
Panacea Acquisition Corp. II (PANA) Delisted	Director	545,000	$10.24	$5.58M	$38.15M	1	2021-04-13

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2023-09-21	Nuvation Bio Inc. (NUVB.WS) Delisted	Buy (P)	+31,878,600	$40.15M	EDGAR
2021-04-13	Nuvation Bio Inc. (NUVB.WS) Delisted	Buy (P)	+3,251,500	$32.16M	EDGAR
2021-04-13	Panacea Acquisition Corp. II (PANA) Delisted	Buy (P)	+3,815,000	$38.15M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.